Gene · 552
AVPR1A: arginine vasopressin receptor 1A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. AVPR1A: arginine vasopressin receptor 1A. Genes, record 552. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/552
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P37288 | Vasopressin V1a receptor | 418 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents37
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 56 | P37288 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37809 | P37288 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3920 | P37288 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3496 | P37288 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 549 | P37288 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 549 | P37288 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3496 | P37288 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3920 | P37288 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6181 | P37288 | Espacenet |
| JP 2023156353 A | 2023-10-24 | 56 | P37288 | Espacenet |
1 to 10 of 37
See all 37 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ARGIPRESSIN TANNATE | CHEMBL2108986 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| BALOVAPTAN | CHEMBL4297183 | Vasopressin V1a receptor antagonist | ANTAGONIST | ChEMBL |
| CONIVAPTAN | CHEMBL1755 | Vasopressin V1a receptor antagonist | ANTAGONIST | ChEMBL |
| CONIVAPTAN HYDROCHLORIDE | CHEMBL1201108 | Vasopressin V1a receptor antagonist | ANTAGONIST | ChEMBL |
| DESMOPRESSIN | CHEMBL1429 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| DESMOPRESSIN ACETATE | CHEMBL1200556 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| LYPRESSIN | CHEMBL1200690 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| PECAVAPTAN | CHEMBL4594444 | Vasopressin V1a receptor antagonist | ANTAGONIST | ChEMBL |
| RELCOVAPTAN | CHEMBL419667 | Vasopressin V1a receptor antagonist | ANTAGONIST | ChEMBL |
| SELEPRESSIN | CHEMBL1817709 | Vasopressin V1a receptor agonist | AGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials165
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07460908 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07423156 | VASOPRESSIN | PHASE3 | ClinicalTrials.gov | |
| NCT07328529 | SRX246 | PHASE2 | ClinicalTrials.gov | |
| NCT07304466 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07255378 | VASOPRESSIN | ClinicalTrials.gov | ||
| NCT07252401 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07233850 | TERLIPRESSIN | PHASE2 | ClinicalTrials.gov | |
| NCT07179991 | DESMOPRESSIN | ClinicalTrials.gov | ||
| NCT07052084 | VASOPRESSIN | PHASE3 | ClinicalTrials.gov | |
| NCT07028645 | DESMOPRESSIN | ClinicalTrials.gov |
1 to 10 of 165
See all 165 trialsNIH grants928
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AVPR1A papers | Newest fiscal year |
|---|---|---|---|
| P51OD011132 | Emory National Primate Research Center | 24 | 2025 |
| P51OD011107 | California National Primate Research Center | 15 | 2025 |
| P30AG028740 | University of Florida Older Americans Independence Center (OAIC) | 7 | 2025 |
| R35GM126940 | Emergent cellular functions of GPCRs and myosins | 4 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 4 | 2025 |
| I01BX004102 | Oxytocin Signaling in the Control of Cardiometabolic Function in Diet-Induced Obesity | 3 | 2025 |
| P30DK034989 | Yale Liver Center | 3 | 2025 |
| R01HD098117 | Mechanisms of maternal brain changes with birth interventions | 3 | 2025 |
| T32MH015144 | Research Training in Mood and Anxiety Disorders: From Animal Models to Patients | 3 | 2025 |
| I01BX002773 | A Novel Drug Target for Aggressive Prostate Cancer | 2 | 2025 |
1 to 10 of 928Source NIH's project files
See all 928 nih grantsPapers1,367
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SOMATODENDRITIC VASOPRESSIN RELEASE COUPLES INTRINSIC EXCITABILITY TO POPULATION-LEVEL ACTIVITY. | bioRxiv | 2026 | 42818055 | PubTator, text mining | PubMed |
| Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review. | Int J Mol Sci | 2026 | 42653310 | PubTator, text mining | PubMed |
| A Multi-Method Approach to Investigate the Toxicity of Aristolochic Acid on Upper Tract Urothelial Carcinoma. | Curr Med Chem | 2026 | 42565416 | PubTator, text mining | PubMed |
| A yeast recombination system recapitulates the length polymorphism of a microsatellite implicated in human social behavior. | NAR Mol Med | 2026 | 42367581 | PubTator, text mining | PubMed |
| Expression and prognostic value of cholesterol homeostasis genes in hepatocellular carcinoma: A cohort study based on TCGA. | Medicine (Baltimore) | 2026 | 42175500 | PubTator, text mining | PubMed |
| Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases. | Biomedicines | 2026 | 42072430 | PubTator, text mining | PubMed |
| Arginine-vasopressin systems in autistic phenotype schizophrenia: effect of a genetic variant of AVPR1a and AVPR1b. | J Neural Transm (Vienna) | 2026 | 42047756 | PubTator, text mining | PubMed |
| Imaging genetics insights into the association between polymorphisms of HPA-axis genes and brain function alterations in depressed adolescents. | J Affect Disord | 2026 | 41935751 | PubTator, text mining | PubMed |
| Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response. | Cancer Immunol Immunother | 2026 | 41925746 | PubTator, text mining | PubMed |
| Molecular Boolean analyses of chemokine (C-C motif) receptor 1, α1B-adrenoceptor and arginine vasopressin receptor 1A heteromers. | Biochem Biophys Rep | 2026 | 41867271 | PubTator, text mining | PubMed |
1 to 10 of 1,367
See all 1,367 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/552
GET https://conductscience.org/api/genes/v1/552/patents?page=2